By Billy Candra 
A groundbreaking study by researchers at the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has unveiled a critical distinction in the function of regulatory T (Treg) cells within colorectal cancer, offering a clear explanation for a long-observed paradox in oncology. While large numbers of Treg cells are typically associated with worse outcomes in most solid tumors—acting as immune system brakes that hinder the body’s ability to combat cancer—colorectal cancer has historically stood out as a perplexing exception, where a higher presence of these cells often correlated with improved patient survival. This new research, published in the scientific journal Immunity, resolves this long-standing mystery by demonstrating that Treg cells are not a monolithic entity but comprise two distinct subtypes with opposing roles in colorectal tumors. This discovery not only promises to significantly enhance immunotherapy strategies for the most common forms of colorectal cancer but also holds potential implications for other cancers arising in barrier tissues such as the skin, stomach, mouth, and throat.
The Colorectal Cancer Paradox Unraveled
For decades, the seemingly contradictory role of regulatory T cells in colorectal cancer baffled oncologists and immunologists alike. In the broader landscape of cancer research, Treg cells are generally viewed as detrimental actors, suppressing the immune response and allowing tumors to evade destruction. Their primary function in a healthy immune system is to maintain "immune tolerance," preventing autoimmune reactions by distinguishing between harmless self-antigens and dangerous pathogens. However, this suppressive capability, when hijacked by cancer, becomes a formidable barrier to effective anti-tumor immunity. The observed correlation between increased Treg cells and better survival in colorectal cancer thus presented a significant anomaly, challenging conventional understanding and hindering the development of targeted therapies.
The MSK study, co-senior authored by Alexander Rudensky, PhD, Chair of the Immunology Program at MSK and a Howard Hughes Medical Institute Investigator, provides the definitive answer. "Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles—one restrains tumor growth, while the other fuels it," Dr. Rudensky explained. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches." This revelation fundamentally reshapes our understanding of the tumor microenvironment in colorectal cancer, shifting the focus from mere cell quantity to their specific functional phenotypes.
A Legacy of Immunological Discovery Leads to Breakthrough
This pivotal research is the culmination of more than 20 years of dedicated scientific inquiry by Dr. Rudensky, recognized globally as a leading authority on regulatory T cells. His pioneering work established the fundamental principles of Treg cell function, elucidating how these cells are generated, how they exert their suppressive effects, and their critical role in maintaining immune homeostasis. From demonstrating their involvement in preventing autoimmune diseases to uncovering their complex influence on cancer development, Dr. Rudensky’s lab has consistently pushed the boundaries of immunological understanding.
The current study was spearheaded by a collaborative team of first authors: Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, who also served as a co-senior author. Their combined expertise in immunology, oncology, and computational biology was instrumental in dissecting the intricate cellular interactions within the colorectal tumor microenvironment.
Focusing on the Most Common Form of Colorectal Cancer
Colorectal cancer (CRC) represents a significant global health challenge, ranking as the second leading cause of cancer-related death when statistics for men and women are combined, according to the American Cancer Society. The MSK study specifically honed in on the most prevalent form of the disease, which accounts for approximately 80% to 85% of all colorectal cancers. These tumors are characterized as microsatellite stable (MSS) with proficient mismatch repair (MMRp), meaning their DNA exhibits relative stability. This particular subgroup of CRC has notoriously shown poor responsiveness to conventional checkpoint inhibitor immunotherapies, a class of drugs that have revolutionized treatment for other cancer types.
In stark contrast, earlier research at MSK and elsewhere has demonstrated the remarkable efficacy of checkpoint inhibitors against the opposite tumor type: cancers with high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd). For these patients, immunotherapy alone can often lead to durable responses, enabling many to avoid aggressive treatments like surgery, chemotherapy, and radiation. The lack of effective immunotherapy options for the vast majority of MSS-MMRp colorectal cancer patients has been a critical unmet need, making the current MSK findings particularly impactful for a large patient population.
Two Types of Treg Cells with Opposite Effects: The Core Discovery
To unravel the unique immune landscape of common colorectal cancers, the research team utilized a sophisticated mouse model developed at MSK. This model meticulously mimics the genetic alterations, pathological behavior, and immune environment characteristic of human colorectal tumors, providing a highly relevant platform for studying disease mechanisms. Through meticulous analysis, they made a pivotal observation: tumor-associated Treg cells could be clearly categorized into two main groups based on their cytokine production.
One group of Treg cells was found to produce a crucial signaling molecule, or cytokine, called interleukin-10 (IL-10). The other group did not. This distinction proved to be the key to understanding their divergent roles.
Through a series of detailed experiments involving the selective removal of each Treg cell group, the researchers precisely mapped their respective impacts on tumor growth:
-
IL-10-positive Treg cells: These cells were identified as beneficial, actively slowing tumor growth. Their mechanism involves reducing the activity of Th17 cells, another type of immune cell known to produce interleukin 17 (IL-17). IL-17, in turn, acts as a growth signal for tumors. By dampening Th17/IL-17 activity, IL-10-positive Treg cells effectively suppress tumor proliferation. Significantly, these protective Treg cells were found to be more prevalent in the healthy tissue immediately surrounding the tumor rather than deep within its core. When these IL-10-positive Treg cells were experimentally depleted, tumors in the mouse models grew more rapidly, confirming their anti-tumor role.
-
IL-10-negative Treg cells: In stark contrast, these cells exhibited a harmful effect, promoting tumor progression. Their primary mechanism of action involves suppressing powerful immune defenders, particularly CD8+ T cells, which are widely recognized for their potent cancer-fighting abilities. These detrimental Treg cells were predominantly located within the tumor itself, where they could most effectively neutralize anti-tumor immune responses. When IL-10-negative Treg cells were selectively eliminated in the experiments, tumors dramatically shrank, underscoring their pro-tumorigenic function.
Patient Data Confirms the Findings: A Translational Validation
The robustness of these findings was further strengthened by their validation in human colorectal cancer samples. The research team meticulously analyzed tumor tissues from patients, confirming the presence of these two distinct populations of IL-10-positive and IL-10-negative Treg cells. This translational step is crucial, bridging observations from preclinical models to direct relevance in human disease.
Beyond cellular identification, the researchers conducted a comprehensive analysis of outcomes for over 100 colorectal cancer patients. The results were striking and directly mirrored their experimental findings: patients whose tumors contained higher levels of the beneficial IL-10-positive Treg cells experienced significantly longer survival. Conversely, patients whose tumors harbored a greater proportion of the harmful IL-10-negative Treg cells faced poorer clinical outcomes.
"This research shows how important these positive cells are," stated Dr. Huang. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones." This sentiment underscores the paradigm shift from broad immune suppression to highly targeted intervention.
Targeting CCR8 as a New Treatment Strategy: A Precision Approach
The identification of these functionally distinct Treg cell subtypes opens a promising new avenue for improving treatment for the vast majority of colorectal cancer patients, particularly those with MSS-MMRp disease who currently lack effective immunotherapy options. The MSK researchers made another critical discovery: the harmful IL-10-negative Treg cells consistently expressed high levels of a specific protein called CCR8. Importantly, these CCR8-high cells were precisely the ones responsible for suppressing the immune response and were predominantly localized within the tumor microenvironment.
This finding builds directly upon earlier, foundational work from Dr. Rudensky’s lab, led by breast cancer surgeon George Plitas, MD. That research had previously demonstrated that CCR8 is also highly expressed on tumor-associated Treg cells in breast cancer and numerous other human malignancies. This earlier work had already suggested the exciting possibility of using antibodies to selectively deplete these harmful, CCR8-expressing Treg cells. The premise was that such targeted depletion could unleash the immune system to more effectively attack tumors while leaving the beneficial Treg cells—and their crucial role in preventing autoimmunity—intact.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky affirmed. This statement highlights the significant impact of MSK’s research on the global immunotherapy landscape. Indeed, multiple clinical trials are now actively testing this innovative approach at MSK and other leading institutions worldwide. These trials are evaluating CCR8-targeting antibodies both as monotherapy and in combination with existing immunotherapies, aiming to maximize anti-tumor efficacy. The new study provides compelling evidence, strengthening the rationale for deploying this strategy specifically in colorectal cancer and potentially extending its application to a broader spectrum of malignancies.
Similar Immune Patterns in Other Cancers: Broader Horizons
The implications of the MSK study extend beyond colorectal cancer. To explore the broader relevance of their findings, the researchers conducted an extensive analysis of a large dataset of T cells derived from 16 different cancer types. Their investigation revealed similar divisions between IL-10-positive and IL-10-negative Treg cell populations in several other cancers, particularly those affecting barrier tissues such as the skin and the lining of the mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," explained Dr. Mitra, who led the extensive data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. This shared characteristic suggests a conserved immunological mechanism across these barrier tissues. Consequently, the team postulates that therapeutic strategies designed to remove IL-10-negative Treg cells in colorectal cancer could also prove effective against these other cancers that arise in similar anatomical sites, opening up exciting possibilities for cross-cancer treatment applications.
A Different Immune Balance in Metastatic Disease: The Need for Nuance
The study also delved into the immune landscape of metastatic colorectal cancer, specifically examining tumors that had spread to the liver. Here, the researchers observed a distinctly different immune pattern compared to primary tumors. In these metastatic lesions, the harmful IL-10-negative Treg cells were found to greatly outnumber their helpful IL-10-positive counterparts. This altered balance suggests a more pronounced immunosuppressive environment in advanced disease.
Intriguingly, unlike primary tumors, removing all Treg cells in this metastatic context resulted in the shrinkage of the tumors. This finding underscores a critical point: treatment strategies must be highly nuanced, taking into account not only the specific tissue involved but also the stage of the disease. A "one-size-fits-all" approach to Treg modulation may not be optimal, and indeed, could be counterproductive, across all disease contexts. This insight paves the way for the development of adaptive and personalized immunotherapy regimens for metastatic disease.
The Path Forward: Clinical Translation and Future Directions
The findings from Memorial Sloan Kettering Cancer Center represent a significant leap forward in understanding and potentially treating colorectal cancer. By resolving a decades-long paradox, identifying distinct Treg cell subtypes with opposing functions, and pinpointing a specific therapeutic target in CCR8, the research team has laid a robust foundation for next-generation immunotherapies. The ongoing clinical trials targeting CCR8 are a testament to the rapid translation of these laboratory discoveries into potential patient benefit.
The comprehensive nature of this study, encompassing mouse models, human patient samples, and broad multi-cancer analyses, exemplifies the rigorous scientific approach required to unravel complex biological mysteries. The collaborative effort involving immunologists, oncologists, and computational biologists highlights the interdisciplinary nature of modern cancer research. As clinical trials progress and further research elucidates the full spectrum of Treg cell diversity and function, the promise of more effective, precisely targeted immunotherapies for colorectal cancer and beyond draws closer to reality, offering new hope to countless patients worldwide.
Acknowledgements and Funding
Additional authors who contributed to this extensive research include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh. The Integrated Genomics Operation and the Single Cell Research Initiative at MSK provided invaluable support and resources for the research.
This study was made possible through significant funding from various prestigious organizations, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
Dr. Rudensky disclosed serving on scientific advisory boards and holding equity in several biotechnology and pharmaceutical companies, including Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity. Importantly, Dr. Rudensky and Dr. Plitas are recognized as inventors on patents and patent applications held by MSK, which are related to CCR8-based therapeutic depletion of tumoral Treg cells and the development of novel antibodies against CCR8, underscoring the direct translational potential and intellectual property generated by this pioneering research.
